Nabriva Therapeutics (NBRV) Given News Sentiment Score of 0.18

Media headlines about Nabriva Therapeutics (NASDAQ:NBRV) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Nabriva Therapeutics earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.1761520698603 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Here are some of the media headlines that may have effected Accern Sentiment’s analysis:

How to Become a New Pot Stock Millionaire

A number of equities analysts recently weighed in on NBRV shares. Cantor Fitzgerald set a $16.00 price target on Nabriva Therapeutics and gave the stock a “buy” rating in a report on Friday, March 16th. Bank of America started coverage on Nabriva Therapeutics in a report on Wednesday. They issued a “buy” rating and a $10.00 price target for the company. Wedbush reaffirmed an “outperform” rating on shares of Nabriva Therapeutics in a report on Monday, March 19th. Morgan Stanley started coverage on Nabriva Therapeutics in a report on Wednesday, January 17th. They issued an “overweight” rating and a $10.00 price target for the company. Finally, Zacks Investment Research cut Nabriva Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday. Two research analysts have rated the stock with a sell rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $16.69.

NBRV stock traded down $0.12 during midday trading on Friday, reaching $5.51. The company had a trading volume of 205,027 shares, compared to its average volume of 375,197. The firm has a market cap of $206.71, a PE ratio of -2.33 and a beta of 1.87. Nabriva Therapeutics has a 12 month low of $4.75 and a 12 month high of $14.10.

WARNING: This article was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3296744/nabriva-therapeutics-nbrv-given-news-sentiment-score-of-0-18.html.

About Nabriva Therapeutics

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Insider Buying and Selling by Quarter for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Zacks: Brokerages Anticipate Simpson Manufacturing  Will Announce Quarterly Sales of $238.34 Million
Zacks: Brokerages Anticipate Simpson Manufacturing Will Announce Quarterly Sales of $238.34 Million
Positive News Coverage Somewhat Unlikely to Impact Liberty Expedia  Stock Price
Positive News Coverage Somewhat Unlikely to Impact Liberty Expedia Stock Price
Hibbett Sports  Rating Lowered to Hold at ValuEngine
Hibbett Sports Rating Lowered to Hold at ValuEngine
Cheetah Mobile Inc  Receives Average Rating of “Hold” from Brokerages
Cheetah Mobile Inc Receives Average Rating of “Hold” from Brokerages
CVR Refining  Earning Somewhat Positive Media Coverage, Accern Reports
CVR Refining Earning Somewhat Positive Media Coverage, Accern Reports
Somewhat Positive Press Coverage Somewhat Unlikely to Affect Bank of Hope  Stock Price
Somewhat Positive Press Coverage Somewhat Unlikely to Affect Bank of Hope Stock Price


© 2006-2018 Ticker Report. Google+.